Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and commercialization plans during a Barclays analyst discussion in Miami, highlighting its lead retinal program 4D-150 and an earlier-stage effort in cystic fibrosis.
Company overview and platform
Chief Financial Officer August Moretti described 4D Molecular Therapeutics as a “next-generation gene therapy company” founded about 12 years ago. He said the company’s platform is based on directed evolution to develop vectors and capsids that are more tissue-specific, which management believes can enable safer dosing and expand gene therapy into larger market indications.
How 4D-150 is positioned in wet AMD
Chief Commercial and Business Officer Chris Simms said the anti-VEGF market has become increasingly focused on improving durability to reduce the burden of frequent intravitreal injections. He noted the market opportunity, saying the company projects the overall anti-VEGF market could be about $20 billion around its expected launch window.
Simms framed 4D-150 as a genetic medicine approach designed to continuously express aflibercept (Eylea), aiming for durability measured in years rather than incremental extensions of weeks. He said the company believes 4D-150 has the potential to reduce treatment burden by 80% to 90% and, for some patients, could be “the last injection they need for the rest of their lives.”
Differentiation, delivery, and safety
Simms emphasized that 4D-150 is delivered via a simple intravitreal injection, which he said fits more seamlessly into busy retina clinic workflows than approaches requiring subretinal surgery. He also said the company believes it has addressed historic safety challenges of intravitreal gene therapy through its internally developed R100 capsid, which was developed using a non-human primate model and designed to target retinal tissue more specifically.
According to Simms, tissue targeting enables lower dosing while maintaining efficacy. He said the Phase 3 dose is 3E10. He added that the company uses a prophylactic steroid regimen in its clinical trials, with steroids administered up to 20 weeks with tapering, as an added safety measure during the period when the capsid is wearing off.
Phase 2 results and Phase 3 timelines
Management discussed Phase 2 datasets from PRISM (wet AMD) and SPECTRA (DME). Simms described PRISM as initially enrolling “hardest to treat” wet AMD patients who had averaged about 10 injections in the prior year and still had elevated central subfield thickness (CST) levels above 400. He said that in a subcohort with two years of follow-up, treatment burden was reduced by about 80% over two years, with patients receiving an average of about four supplemental injections versus an expected pace of roughly 20, while CST and vision were maintained.
Simms also discussed PRISM patients who were more recently diagnosed (within the prior six months), which he said more closely resembles the company’s Phase 3 treatment-naïve population. In that group, he said the company observed about a 90% treatment burden reduction out to 18 months, with about 73% of patients injection-free at 18 months.
On safety, Simms said the intraocular inflammation rate observed was less than 3% and characterized the overall safety profile as consistent with standard of care expectations.
Regarding the Phase 3 program, Simms said enrollment has progressed quickly. He said the company recently announced full enrollment in 4FRONT-1, with a readout expected in the first half of 2027. Enrollment for 4FRONT-2 is on track, with enrollment completion guided for the second half of this year and a data readout expected in the second half of 2027.
Simms added that the company initially targeted 18 months for enrollment and completed 4FRONT-1 in about 11 months. He also said the trial was upsized from an initial target of 400 patients and that enrollment is expected to end “north of 500.”
DME strategy, cystic fibrosis update, and financial runway
Simms said DME represents a large market (behind wet AMD) and argued unmet need may be greater because patients are often more undertreated and discontinue bolus therapies earlier. Management said it has alignment with the FDA and EMA on a single DME trial and hopes to start the Phase 3 DME program in Q3 of this year as a global study. Simms noted that 4D-150 is partnered with Otsuka, which holds Asia Pacific rights, and that Asia Pacific would be included in the global DME program.
On cystic fibrosis, management said an update is expected in the second half of the year, but it has not provided full guidance on what will be disclosed. Moretti said the company is working with the Cystic Fibrosis Foundation, which he said is largely funding the program, and plans to design a Phase 2 study in collaboration with regulators. Simms said the goal is to ultimately have data on 12 patients with 12 months of follow-up to inform the program’s direction.
Moretti said the company ended last year with $514 million in cash and is guiding to a cash runway into the second half of 2028, which he said funds the company well past the 4FRONT-1 and 4FRONT-2 readouts but does not fund the commercial ramp-up planned after 4FRONT-1. He also said the cost of goods sold for 4D-150 is expected to be below $1,000 per injection, which management said provides flexibility on pricing and supports scalability.
Simms said the retina market can be commercialized with a relatively lean footprint, estimating an overall commercial employee count around 120 to 130, including about 60 field personnel. He said the company’s plan is to commercialize on its own in the U.S. and potentially in Europe.
On pricing and practice economics, Simms said the company expects to be flexible and prioritize broad patient access, arguing 4D-150 should not be positioned as a niche product. He also said the economics for clinics could be favorable under buy-and-bill reimbursement, describing value from an upfront reimbursement tied to a higher price point than a single bolus injection, as well as potential benefits from addressing patient drop-off from existing bolus therapies.
About 4D Molecular Therapeutics (NASDAQ:FDMT)
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.
Further Reading
- Five stocks we like better than 4D Molecular Therapeutics
- The $8,000 Gold Call Every Retirement Saver Needs to Read Right Now
- A personal warning from Martin Weiss (Please read)
- Elon Musk: This Could Turn $100 into $100,000
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- America’s gold reserves are priced at $42. The real price is $6,000+.
